Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis
返回论文页
|更新时间:2023-06-12
|
Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis
SHAO Qianhang,LIU Xuemei,HUANG Lin,et al.Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis[J].ZHONGGUO YAOFANG,2023,34(05):600-606.
SHAO Qianhang,LIU Xuemei,HUANG Lin,et al.Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis[J].ZHONGGUO YAOFANG,2023,34(05):600-606. DOI: 10.6039/j.issn.1001-0408.2023.05.17.
Efficacy and safety of 4 kinds of hemocoagulases combined with proton pump inhibitor for nonvariceal upper gastrointestinal bleeding:a network meta-analysis
计算机检索PubMed、Web of Science、万方数据、维普网、中国知网数据库中关于白眉蛇毒血凝酶、尖吻蝮蛇血凝酶、蛇毒血凝酶、矛头蝮蛇血凝酶联合PPI治疗NVUGIB的随机对照试验(RCT)或队列研究,检索时间为建库起至2021年12月;由2位研究人员独立筛选文献、提取资料并评价纳入文献质量后,运用ADDIS 1.16.8软件进行贝叶斯网状Meta分析。
To systematically evaluate the difference of efficacy and safety of four kinds of commonly used haemocoagulases combined with proton pump inhibitor (PPI) for nonvariceal upper gastrointestinal bleeding (NVUGIB), and to provide evidence-based basis for clinical decision-making.
METHODS
2
Retrieved from PubMed, Web of Science, Wanfang data, VIP and CNKI databases, randomized controlled trials (RCTs) or cohort studies about
Hemocoagulase agkistrodon blomhoffii
,
Haemocoagulase agkistrodon
, hemocoagulase and
Hemocoagulase bothrops atrox
combined with PPI were collected during the inception to Dec. 2021. Two researchers independently screened the literature, extracted data and evaluated the quality of included studies. ADDIS 1.16.8 software was used to conduct a Bayesian network meta-analysis.
RESULTS
2
A total of 33 studies were included, involving 3 602 patients. Results of network meta-analysis showed that: in terms of hemostatic efficacy, compared with PPI monotherapy, four kinds of haemocoagulases combined with PPI could significantly improve the hemostatic efficacy of patients (
P
<0.05); there was no statistical significance in the pairwise comparison of different hemocoagulases (
P
>0.05). The optimal probabilistic ranking of network meta-analysis was as follows:
Hemocoagulase agkistrodon blomhoffii
combined with PPI>
Hemocoagulase bothrops atrox
combined with PPI>
Haemocoagulase agkistrodon
combined with PPI>hemocoagulase combined with PPI>PPI alone. In terms of the incidence of adverse drug reactions (ADR), compared with PPI monotherapy, there was no statistical difference in the incidence of ADR among four kinds of haemocoagulases combined with PPI (
P
>0.05). There was no statistical significance in the pairwise comparison of different hemocoagulases (
P
>0.05). The optimal probabilistic ranking of network meta-analysis was as follows: hemocoagulase combined with PPI>
Hemocoagulase bothrops atrox
combined with PPI>
Hemocoagulase agkistrodon blomhoffii
combined with PPI>
Haemocoagulase agkistrodon
combined with PPI>PPI alone.
CONCLUSIONS
2
Compared with PPI monotherapy, four different sources of hemocoagulases combined with PPI have better efficacy and similar safety in the treatment of NVUGIB. There is no significant difference in efficacy and safety among different hemocoagulases.
Network meta-analysis of triple therapy for the prevention and treatment of acute nausea and vomiting caused by emetogenic chemotherapy drugs with moderate and high risk
Pharmacotherapy plan for metastatic hormone-sensitive prostate cancer:a network meta-analysis
Network meta-analysis of the efficacy and safety of different drug regimens in the treatment of children with Kawasaki disease
Network meta-analysis of SGLT-2 inhibitor-induced hypoglycemia risk in type 2 diabetes patients
Clinical observation of 9 cases of rituximab followed by belimumab in the treatment of severe systemic lupus erythematosus
Related Author
JIN Pengfei
WANG Yang
ZHANG Yatong
LI Ting
ZHANG Tian
CHEN Wanyi
TANG Zongwei
SONG Haichi
Related Institution
Dept. of Pharmacy, Beijing Hospital/National Center of Gerontology/Institute of Geriatric Medicine, Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital)
Dept. of Pharmacy, Chongqing University Cancer Hospital
Dept. of Cardiovascular Medicine, Shunde Hospital of Southern Medical University (Shunde District First People’s Hospital of Foshan)
Dept. of Pediatrics, Shunde Hospital of Southern Medical University (Shunde District First People’s Hospital of Foshan)
Dept. of Pharmacy, the Affiliated Hospital of Shaanxi University of Chinese Medicine